In recent years, a range of targeted treatment agents have been developed for NSCLC, including small-molecule inhibitors of the EGFR, ALK, ROS1 and KRASG12C mutated proteins.3 The gene discussed is ROS1; the disease is non-small cell lung carcinoma.